Braveheart Bio, Inc. (NASDAQ:BRVE) Stock Has Average Price Target of $45.25 According to Analysts

Posted by Brian Himes on Oct 2nd, 2026

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $45.25.

Several analysts recently weighed in on the company. The Goldman Sachs Group assumed coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 price objective on the stock. Stifel Nicolaus began coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $45.00 target price for the company. TD Cowen assumed coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating on the stock. Cantor Fitzgerald initiated coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set an “overweight” rating and a $40.00 price target on the stock. Finally, Jefferies Financial Group started coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 price objective for the company.

Read Our Latest Stock Analysis on Braveheart Bio

Braveheart Bio Stock Performance

Shares of BRVE opened at $21.41 on Friday. Braveheart Bio has a one year low of $19.88 and a one year high of $32.00.

Braveheart Bio (NASDAQ:BRVE – Get Free Report) last issued its earnings results on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). Research analysts forecast that Braveheart Bio will post -1.48 EPS for the current year.

Insider Activity

In other news, major shareholder Bio Fund Iv L.P. Ah purchased 1,100,000 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $19,800,000.00. Following the purchase, the insider owned 10,232,420 shares of the company’s stock, valued at approximately $184,183,560. The trade was a 12.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Lubner acquired 55,555 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $999,990.00. Following the acquisition, the director owned 55,555 shares in the company, valued at $999,990. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 8,751,942 shares of company stock valued at $157,534,956.

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.